$ZKIN
ZK International Group Co., Ltd. Stock $zkin

$zkin Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 20-F Financial Statement

#000141057824001331 Filed on August 13, 2024

Income Statement

Concept	2023 Q3	2023	2022 Q3
Revenue	$61.94M	$111.6M	$59.50M
YoY Change	4.11%	8.99%	3.95%
Cost Of Revenue	$63.82M	$110.3M	$55.87M
YoY Change	14.22%	16.36%	0.72%
Gross Profit	-$1.872M	$1.296M	$3.628M
YoY Change	-151.6%	-82.93%	105.76%
Gross Profit Margin	-3.02%	1.16%	6.1%
Selling, General & Admin	$4.855M	$7.262M	$4.639M
YoY Change	4.65%	-6.92%	-6.38%
% of Gross Profit		560.17%	127.85%
Research & Development	$654.8K	$1.274M	$427.0K
YoY Change	53.37%	29.09%
% of Gross Profit		98.3%	11.77%
Depreciation & Amortization		$677.3K	$1.162M
YoY Change		0.73%	49.32%
% of Gross Profit		52.24%	32.03%
Operating Expenses	$5.510M	$61.74M	$5.066M
YoY Change	8.75%	434.07%	34.38%
Operating Profit	-$7.382M	-$60.44M	-$1.438M
YoY Change	413.49%	1424.58%	-28.36%
Interest Expense	-$1.186M	$1.584M	-$2.881M
YoY Change	-58.85%	-54.12%	369.89%
% of Operating Profit
Other Income/Expense, Net	$77.79K	-$1.307M	-$306.4K
YoY Change	-125.39%	-61.91%	-389.33%
Pretax Income	-$61.69M	-$61.75M	-$7.396M
YoY Change	734.1%	735.01%	194.23%
Income Tax	-$459.9K	-$459.9K	-$1.341M
% Of Pretax Income
Net Earnings	-$61.01M	-$61.06M	-$6.073M
YoY Change	904.52%	904.06%	88.78%
Net Earnings / Revenue	-98.48%	-54.71%	-10.21%
Basic Earnings Per Share		-$1.94
Diluted Earnings Per Share	-$1.88	-$1.94	-$204.5K
COMMON SHARES
Basic Shares Outstanding	32.99M	31.45M	30.39M
Diluted Shares Outstanding		31.45M

Balance Sheet

Concept	2023 Q3	2023	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.043M	$5.043M	$8.431M
YoY Change	-40.19%	-40.19%	-47.59%
Cash & Equivalents	$4.994M	$4.994M	$7.515M
Short-Term Investments	$48.15K	$48.15K	$915.6K
Other Short-Term Assets	$4.861M	$4.861M	$6.425M
YoY Change	-24.34%	-24.34%	-49.19%
Inventory	$17.94M	$17.94M	$21.14M
Prepaid Expenses
Receivables	$14.97M	$14.97M	$28.36M
Other Receivables	$438.2K	$438.2K	$2.410M
Total Short-Term Assets	$43.25M	$43.25M	$66.77M
YoY Change	-35.23%	-35.23%	-15.16%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.836M	$7.880M	$7.125M
YoY Change	9.99%	10.12%	-11.59%
Goodwill
YoY Change
Intangibles	$1.437M		$11.42M
YoY Change	-87.41%		30.46%
Long-Term Investments	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Assets	$577.6K	$577.6K	$36.06M
YoY Change	-98.4%	-98.4%	40.44%
Total Long-Term Assets	$15.42M	$15.42M	$62.15M
YoY Change	-75.19%	-75.19%	13.09%
TOTAL ASSETS
Total Short-Term Assets	$43.25M	$43.25M	$66.77M
Total Long-Term Assets	$15.42M	$15.42M	$62.15M
Total Assets	$58.67M	$58.67M	$128.9M
YoY Change	-54.49%	-54.49%	-3.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.611M	$2.611M	$10.07M
YoY Change	-74.06%	-74.06%	366.11%
Accrued Expenses	$6.905M	$6.864M	$8.841M
YoY Change	-21.9%	-21.53%	0.98%
Deferred Revenue	$821.7K		$1.759M
YoY Change	-53.28%		-68.96%
Short-Term Debt	$4.052M	$4.052M	$20.31M
YoY Change	-80.05%	-80.05%	-16.12%
Long-Term Debt Due	$9.389M	$9.389M	$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$24.89M	$24.89M	$43.85M
YoY Change	-43.24%	-43.24%	-1.49%
LONG-TERM LIABILITIES
Long-Term Debt	$8.528M	$8.528M	$0.00
YoY Change
Other Long-Term Liabilities	$11.81K	$11.81K	$10.26K
YoY Change	15.11%	15.11%	-63.13%
Total Long-Term Liabilities	$8.540M	$8.540M	$10.26K
YoY Change	83130.99%	83130.99%	-63.13%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.89M	$24.89M	$43.85M
Total Long-Term Liabilities	$8.540M	$8.540M	$10.26K
Total Liabilities	$33.43M	$33.59M	$43.86M
YoY Change	-23.78%	-24.09%	-2.24%
SHAREHOLDERS EQUITY
Retained Earnings	-$47.67M		$13.39M
YoY Change	-455.88%		-32.14%
Common Stock	$72.89M		$70.87M
YoY Change	2.84%		11.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$25.08M	$25.08M	$84.68M
YoY Change
Total Liabilities & Shareholders Equity	$58.67M	$58.67M	$128.9M
YoY Change	-54.49%	-54.49%	-3.55%

Cashflow Statement

Concept	2023 Q3	2023	2022 Q3
OPERATING ACTIVITIES
Net Income	-$61.01M	-$61.06M	-$6.073M
YoY Change	904.52%	904.06%	88.78%
Depreciation, Depletion And Amortization		$677.3K	$1.162M
YoY Change		0.73%	49.32%
Cash From Operating Activities		-$1.906M	$3.790M
YoY Change		-8.03%	401.8%
INVESTING ACTIVITIES
Capital Expenditures		$656.2K	-$1.943M
YoY Change		29.25%	-9.27%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities		-$2.294M	-$1.943M
YoY Change		8.82%	-92.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		2.068M	680.4K
YoY Change		-313.22%	-95.86%
NET CHANGE
Cash From Operating Activities		-1.906M	3.790M
Cash From Investing Activities		-2.294M	-1.943M
Cash From Financing Activities		2.068M	680.4K
Net Change In Cash		-2.572M	2.528M
YoY Change		-57.04%	-125.2%
FREE CASH FLOW
Cash From Operating Activities		-$1.906M	$3.790M
Capital Expenditures		$656.2K	-$1.943M
Free Cash Flow		-$2.562M	$5.733M
YoY Change		-0.69%	97.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2354832
CY2023Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	817059
CY2023Q3	us-gaap	Other Liability Current Related Party Type Extensible Enumeration OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q3	us-gaap	Common Stock Value CommonStockValue
CY2022Q3	us-gaap	Common Stock Value CommonStockValue
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001687451
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	us-gaap	Impairment Of Intangible Asset Finite Lived Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#GeneralAndAdministrativeExpense
CY2023	us-gaap	Impairment Of Intangible Asset Finite Lived Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#GeneralAndAdministrativeExpense
CY2023	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2022Q3	us-gaap	Other Liability Current Related Party Type Extensible Enumeration OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30392940
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32992740
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2571732
CY2023	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32992740
CY2023	us-gaap	Profit Loss ProfitLoss	-61290390
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-47666657
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1905912
CY2023Q3	us-gaap	Short Term Investments ShortTermInvestments	48145
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3190985
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	17897334
CY2022	us-gaap	Depreciation Depreciation	672368
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Type DocumentType	20-F
CY2023	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38146
CY2023	dei	Entity Registrant Name EntityRegistrantName	ZK INTERNATIONAL GROUP CO., LTD.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	D8
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	c/o Zhejiang Zhengkang Industrial Co., Ltd.
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	No. 678 Dingxiang Road, Binhai Industrial Park
CY2023	dei	Entity Address Address Line3 EntityAddressAddressLine3	Economic & Technology Development Zone
CY2023	dei	Security12b Title Security12bTitle	Ordinary shares, no par value per share
CY2023	dei	Trading Symbol TradingSymbol	ZKIN
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	32992740
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Auditor Firm AuditorFirmId	6901
CY2023	dei	Auditor Name AuditorName	Fortune CPA, Inc
CY2023	dei	Auditor Location AuditorLocation	Orange, CA
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4994411
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7515147
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	50995
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	101992
CY2023Q3	us-gaap	Short Term Investments ShortTermInvestments	48145
CY2022Q3	us-gaap	Short Term Investments ShortTermInvestments	915616
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6617485
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	255322
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14967186
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	28362933
CY2023Q3	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	54825
CY2022Q3	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	49611
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	383413
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2360539
CY2023Q3	us-gaap	Inventory Net InventoryNet	17937425
CY2022Q3	us-gaap	Inventory Net InventoryNet	21141501
CY2023Q3	us-gaap	Supplies Supplies	4810044
CY2022Q3	us-gaap	Supplies Supplies	6322592
CY2023Q3	us-gaap	Assets Current AssetsCurrent	43246444
CY2022Q3	us-gaap	Assets Current AssetsCurrent	66769931
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7836017
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7124587
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	43840
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	30998
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1437384
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	11415451
CY2022Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	320164
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	292070
CY2022Q3	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	10447395
CY2023Q3	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	5527682
CY2022Q3	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	7522188
CY2023Q3	us-gaap	Long Term Investments LongTermInvestments	285540
CY2022Q3	us-gaap	Long Term Investments LongTermInvestments	25292866
CY2023Q3	us-gaap	Assets Assets	58668977
CY2022Q3	us-gaap	Assets Assets	128923580
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2611220
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	10066758
CY2023Q3	zkin	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	4964893
CY2022Q3	zkin	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	6949772
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21749
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10754
CY2023Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1918415
CY2022Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1880377
CY2023Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	821694
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1758800
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1111001
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2052403
CY2023Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	4011224
CY2022Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	3352311
CY2023Q3	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	9388706
CY2022Q3	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	16257820
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	41118
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	702889
CY2023Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	669
CY2022Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	817059
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	24890689
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	43848943
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11811
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10256
CY2023Q3	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	8527686
CY2023Q3	us-gaap	Liabilities Liabilities	33430186
CY2022Q3	us-gaap	Liabilities Liabilities	43859199
CY2022Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2023Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32992740
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30392940
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	72886898
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	70872765
CY2023Q3	us-gaap	Statutory Accounting Practices Statutory Capital And Surplus Required StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired	3176556
CY2022Q3	us-gaap	Statutory Accounting Practices Statutory Capital And Surplus Required StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired	3176556
CY2023Q3	us-gaap	Common Stock Share Subscribed But Unissued Subscriptions Receivable CommonStockShareSubscribedButUnissuedSubscriptionsReceivable	125000
CY2022Q3	us-gaap	Common Stock Share Subscribed But Unissued Subscriptions Receivable CommonStockShareSubscribedButUnissuedSubscriptionsReceivable	125000
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-47666657
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	13394137
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3190985
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2640753
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	25080812
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	84677705
CY2023Q3	us-gaap	Minority Interest MinorityInterest	157980
CY2022Q3	us-gaap	Minority Interest MinorityInterest	386676
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	25238792
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	85064381
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	58668977
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	128923580
CY2023	us-gaap	Revenues Revenues	111599686
CY2022	us-gaap	Revenues Revenues	102391636
CY2021	us-gaap	Revenues Revenues	99407217
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	110303270
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	94796037
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	92936029
CY2023	us-gaap	Gross Profit GrossProfit	1296416
CY2022	us-gaap	Gross Profit GrossProfit	7595599
CY2021	us-gaap	Gross Profit GrossProfit	6471188
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2117810
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2380429
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3117906
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5144340
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5421575
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5772710
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	53203517
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2771019
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1274337
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	987186
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1234161
CY2023	us-gaap	Operating Expenses OperatingExpenses	61740004
CY2022	us-gaap	Operating Expenses OperatingExpenses	11560209
CY2021	us-gaap	Operating Expenses OperatingExpenses	10124777
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-60443588
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-3964610
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-3653589
CY2023	us-gaap	Interest Expense InterestExpense	1583734
CY2022	us-gaap	Interest Expense InterestExpense	3451665
CY2021	us-gaap	Interest Expense InterestExpense	1196648
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	36699
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	109290
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	13733
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	50649
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	240378
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-88125
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	431438
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1306657
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3430500
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-700828
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-61750245
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7395110
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4354417
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-459855
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1340844
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-552146
CY2023	us-gaap	Profit Loss ProfitLoss	-61290390
CY2022	us-gaap	Profit Loss ProfitLoss	-6054266
CY2021	us-gaap	Profit Loss ProfitLoss	-3802271
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-229596
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	27147
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2757
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-61060794
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-6081413
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3799514
CY2023	us-gaap	Profit Loss ProfitLoss	-61290390
CY2022	us-gaap	Profit Loss ProfitLoss	-6054266
CY2021	us-gaap	Profit Loss ProfitLoss	-3802271
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-549332
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-5504385
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2423439
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-61839722
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-11558651
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-1378832
CY2023	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-228696
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	62109
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	14773
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-61611026
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11620760
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1393605
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.94
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.94
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31445962
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29305828
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21873594
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31445962
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29431781
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22633819
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	45303729
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	24759560
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	11443067
CY2021	zkin	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	1345056
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	9542783
CY2021	zkin	Adjustment To Additional Paid In Capital Unearned Compensation AdjustmentToAdditionalPaidInCapitalUnearnedCompensation	1891011
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2423439
CY2021	us-gaap	Profit Loss ProfitLoss	-3802271
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	89124352
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1688640
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	116781
CY2022	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	678782
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5603615
CY2022	zkin	Adjustment To Additional Paid In Capital Unearned Compensation AdjustmentToAdditionalPaidInCapitalUnearnedCompensation	589138
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-5504385
CY2022	us-gaap	Profit Loss ProfitLoss	-6054266
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	85064381
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1839733
CY2023	zkin	Adjustment To Additional Paid In Capital Unearned Compensation AdjustmentToAdditionalPaidInCapitalUnearnedCompensation	-174400
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-549332
CY2023	us-gaap	Profit Loss ProfitLoss	-61290390
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	25238792
CY2023	us-gaap	Profit Loss ProfitLoss	-61290390
CY2022	us-gaap	Profit Loss ProfitLoss	-6054266
CY2021	us-gaap	Profit Loss ProfitLoss	-3802271
CY2023	us-gaap	Depreciation Depreciation	677275
CY2022	us-gaap	Depreciation Depreciation	672368
CY2021	us-gaap	Depreciation Depreciation	568038
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	298431
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	830481
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	481763
CY2021	zkin	Right Of Use Assets Non Cash RightOfUseAssetsNonCash	53634
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	17897334
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	227837
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	92032
CY2021	zkin	Write Off Of Advance To Suppliers WriteOffOfAdvanceToSuppliers	108395
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	322897
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	406064
CY2022	us-gaap	Gain Loss On Sale Of Accounts Receivable GainLossOnSaleOfAccountsReceivable	1602500
CY2023	zkin	Intangible Assets And Long Term Investments Impairment Charges IntangibleAssetsAndLongTermInvestmentsImpairmentCharges	35346769
CY2022	zkin	Intangible Assets And Long Term Investments Impairment Charges IntangibleAssetsAndLongTermInvestmentsImpairmentCharges	2771019
CY2023	zkin	Increase Decrease In Unrecognized Tax Benefits IncreaseDecreaseInUnrecognizedTaxBenefits	823340
CY2022	zkin	Increase Decrease In Unrecognized Tax Benefits IncreaseDecreaseInUnrecognizedTaxBenefits	1428458
CY2021	zkin	Increase Decrease In Unrecognized Tax Benefits IncreaseDecreaseInUnrecognizedTaxBenefits	918038
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	2014133
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2674807
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1351082
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	658913
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	1324510
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	210173
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	44458
CY2023	zkin	Interest Expense Of Accounts Receivable Factoring InterestExpenseOfAccountsReceivableFactoring	359051
CY2022	zkin	Interest Expense Of Accounts Receivable Factoring InterestExpenseOfAccountsReceivableFactoring	1151453
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-8165567
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	12059620
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5804654
CY2023	zkin	Increase Decrease In Other Receivables And Prepaid Expenses IncreaseDecreaseInOtherReceivablesAndPrepaidExpenses	-349612
CY2022	zkin	Increase Decrease In Other Receivables And Prepaid Expenses IncreaseDecreaseInOtherReceivablesAndPrepaidExpenses	260755
CY2021	zkin	Increase Decrease In Other Receivables And Prepaid Expenses IncreaseDecreaseInOtherReceivablesAndPrepaidExpenses	-1345520
CY2023	us-gaap	Increase Decrease In Notes Receivable Current IncreaseDecreaseInNotesReceivableCurrent	6676
CY2022	us-gaap	Increase Decrease In Notes Receivable Current IncreaseDecreaseInNotesReceivableCurrent	53853
CY2021	us-gaap	Increase Decrease In Notes Receivable Current IncreaseDecreaseInNotesReceivableCurrent	-201187
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2870541
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2606504
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2021789
CY2023	us-gaap	Increase Decrease In Materials And Supplies IncreaseDecreaseInMaterialsAndSupplies	-1401001
CY2022	us-gaap	Increase Decrease In Materials And Supplies IncreaseDecreaseInMaterialsAndSupplies	-5493624
CY2021	us-gaap	Increase Decrease In Materials And Supplies IncreaseDecreaseInMaterialsAndSupplies	8297301
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-7451608
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	8803924
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-8662576
CY2023	us-gaap	Increase Decrease In Notes Payable Current IncreaseDecreaseInNotesPayableCurrent	-666355
CY2022	us-gaap	Increase Decrease In Notes Payable Current IncreaseDecreaseInNotesPayableCurrent	762986
CY2021	us-gaap	Increase Decrease In Notes Payable Current IncreaseDecreaseInNotesPayableCurrent	-159823
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-1918915
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	752241
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	2428410
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	130063
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	219178
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	211632
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-923844
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3662097
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	3162961
CY2021	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	-77214
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-707470
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-23841
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-28595
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	53635
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1905912
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2072220
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3479064
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	656178
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	507663
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	114319
CY2023	zkin	Payments To Acquire Construction In Progress PaymentsToAcquireConstructionInProgress	930814
CY2022	zkin	Payments To Acquire Construction In Progress PaymentsToAcquireConstructionInProgress	12666
CY2021	zkin	Payments To Acquire Construction In Progress PaymentsToAcquireConstructionInProgress	47942
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	707470
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1588107
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1983812
CY2021	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	25000000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2294462
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2108436
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-27146073
CY2023	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	-852542
CY2022	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	-1523953
CY2021	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	2228301
CY2023	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	21486396
CY2022	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	31113044
CY2021	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	31203129
CY2023	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	19350091
CY2022	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	34501465
CY2021	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	28144978
CY2023	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-920690
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	1173516
CY2021	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-280313
CY2022	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	279004
CY2021	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	483458
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	24758458
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	14071908
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1345056
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2068157
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-969956
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	40241501
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-439515
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-835453
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	227305
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5986065
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9843669
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7617139
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13603204
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3759535
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5045406
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7617139
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13603204
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	38695
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	87473
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	37041
CY2023	us-gaap	Interest Paid Net InterestPaidNet	774929
CY2022	us-gaap	Interest Paid Net InterestPaidNet	976091
CY2021	us-gaap	Interest Paid Net InterestPaidNet	338575
CY2023	zkin	Noncash Investing And Financing Items Due From To Related Party Offset Amount NoncashInvestingAndFinancingItemsDueFromToRelatedPartyOffsetAmount	545844
CY2022	zkin	Noncash Investing And Financing Items Due From To Related Party Offset Amount NoncashInvestingAndFinancingItemsDueFromToRelatedPartyOffsetAmount	623363
CY2021	zkin	Noncash Investing And Financing Items Due From To Related Party Offset Amount NoncashInvestingAndFinancingItemsDueFromToRelatedPartyOffsetAmount	604719
CY2023	zkin	Noncash Investing And Financing Items Intangible Assets Obtained In Exchange For Settlement Of Long Term Deposit NoncashInvestingAndFinancingItemsIntangibleAssetsObtainedInExchangeForSettlementOfLongTermDeposit	707470
CY2022	zkin	Noncash Investing And Financing Items Intangible Assets Obtained In Exchange For Settlement Of Long Term Deposit NoncashInvestingAndFinancingItemsIntangibleAssetsObtainedInExchangeForSettlementOfLongTermDeposit	749252
CY2023Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32992740
CY2015Q3	zkin	Number Of Mainland Chinese Beneficial Owners NumberOfMainlandChineseBeneficialOwners	5
CY2022	us-gaap	Profit Loss ProfitLoss	-6054266
CY2021	us-gaap	Profit Loss ProfitLoss	-3802271
CY2023Q3	zkin	Working Capital WorkingCapital	18376141
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of the consolidated financial statements in conformity with generally accepted accounting principles in the United States of America (US GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Such estimates include, but are not limited to, expected credit loss of accounts receivable, inventory valuation, useful life of property, plant and equipment, intangible asset impairment, allowances of long-term prepayment, long-term investment impairment, and income taxes related to realization of deferred tax assets and uncertain tax position. Actual results could differ from those estimates.</p>
CY2023Q3	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	7.2960
CY2022Q3	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	7.1135
CY2021Q3	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	6.4434
CY2023Q3	zkin	Average Foreign Currency Exchange Rate Translation AverageForeignCurrencyExchangeRateTranslation	7.0533
CY2022Q3	zkin	Average Foreign Currency Exchange Rate Translation AverageForeignCurrencyExchangeRateTranslation	6.5532
CY2021Q3	zkin	Average Foreign Currency Exchange Rate Translation AverageForeignCurrencyExchangeRateTranslation	6.5072
CY2022Q3	us-gaap	Short Term Investments ShortTermInvestments	915616
CY2021Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	12472847
CY2022	zkin	Number Of Proposed Acquisitions Terminated NumberOfProposedAcquisitionsTerminated	2
CY2022Q3	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	10447395
CY2022Q3	zkin	Acquired Patent Appraised Value AcquiredPatentAppraisedValue	4990000
CY2023	zkin	Long Term Deposit Writeoff LongTermDepositWriteoff	9830000
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6617485
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	255322
CY2022Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	102365
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	10346769
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	2771019
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2018Q2	zkin	Value Added Taxes Rate ValueAddedTaxesRate	0.17
CY2018Q2	zkin	Value Added Taxes Rate ValueAddedTaxesRate	0.16
CY2019Q2	zkin	Value Added Taxes Rate ValueAddedTaxesRate	0.13
CY2023	us-gaap	Dividends Common Stock DividendsCommonStock	0
CY2023Q3	zkin	Holding Percentage Of Sig Token Issued And Outstanding HoldingPercentageOfSigTokenIssuedAndOutstanding	0.30
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	337216
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	496740
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	446480
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2640000
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	322897
CY2023	us-gaap	Advertising Expense AdvertisingExpense	19972
CY2022	us-gaap	Advertising Expense AdvertisingExpense	77781
CY2021	us-gaap	Advertising Expense AdvertisingExpense	104661
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2640753
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Concentration of Risks</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Exchange Rate Risks</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company operates in China, which may give rise to significant foreign currency risks mainly from fluctuations and the degree of volatility of foreign exchange rates between the USD and the RMB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Currency Convertibility Risks</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Substantially all of the Company’s operating activities are transacted in RMB, which is not freely convertible into foreign currencies. All foreign exchange transactions take place either through the People’s Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the People’s Bank of China. Approval of foreign currency payments by the People’s Bank of China or other regulatory institutions requires submitting a payment application form together with other information such as suppliers’ invoices, shipping documents and signed contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Concentration of Credit Risks</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Financial instruments that potentially subject the Company to concentration of credit risks consist primarily of cash and cash equivalents, short-term investment, notes receivable, accounts receivable and other receivables, the balances of which are stated on the consolidated balance sheets which represent the Company’s maximum exposure. The Company places its cash and cash equivalents, and short-term investment in good credit quality financial institutions in Hong Kong and China. Concentration of credit risks with respect to accounts receivables is linked to the concentration of revenue. To manage credit risk, the Company performs ongoing credit evaluations of customers’ financial condition. The concentration analysis of our revenue and accounts receivable is shown in Note 17.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Interest Rate Risks</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company is subject to interest rate risk. The Company has bank interest bearing loans charged at variable interest rates. And although some bank interest bearing loans are charged at fixed interest rates within the reporting period, the Company is still subject to the risk of adverse changes in the interest rates charged by the banks when these loans are refinanced.</p>
CY2023Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	21584671
CY2022Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	28618255
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6617485
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	255322
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14967186
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	28362933
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	227837
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	255322
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2221870
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	6366356
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	192298
CY2023	zkin	Allowance For Doubtful Accounts Reduction Due To Factoring AllowanceForDoubtfulAccountsReductionDueToFactoring	0
CY2022	zkin	Allowance For Doubtful Accounts Reduction Due To Factoring AllowanceForDoubtfulAccountsReductionDueToFactoring	2104366
CY2023	zkin	Allowance For Doubtful Accounts Receivable Exchange Difference AllowanceForDoubtfulAccountsReceivableExchangeDifference	-4193
CY2022	zkin	Allowance For Doubtful Accounts Receivable Exchange Difference AllowanceForDoubtfulAccountsReceivableExchangeDifference	-54480
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6617485
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	255322
CY2010	zkin	Number Of Loan Agreements NumberOfLoanAgreements	2
CY2010	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	10500000
CY2010	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	1520000
CY2010	zkin	Number Of Loan Agreements NumberOfLoanAgreements	2
CY2010	us-gaap	Debt Instrument Term DebtInstrumentTerm	P1Y
CY2010	zkin	Number Of Other Parties Sued NumberOfOtherPartiesSued	2
CY2010	us-gaap	Litigation Settlement Amount Awarded From Other Party LitigationSettlementAmountAwardedFromOtherParty	10500000
CY2010	zkin	Litigation Settlement Repayment Interest Percentage Multiplier LitigationSettlementRepaymentInterestPercentageMultiplier	4
CY2010	us-gaap	Litigation Settlement Amount Awarded From Other Party LitigationSettlementAmountAwardedFromOtherParty	10500000
CY2010Q3	us-gaap	Other Receivables OtherReceivables	10500000
CY2023Q3	us-gaap	Other Receivables OtherReceivables	4400000
CY2023Q3	us-gaap	Other Receivables OtherReceivables	600000
CY2022Q3	us-gaap	Other Receivables OtherReceivables	4400000
CY2022Q3	us-gaap	Other Receivables OtherReceivables	620000
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	623821
CY2023Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	4551761
CY2022Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	5609999
CY2023Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	6133081
CY2022Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	8170837
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7252583
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7463030
CY2022Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	102365
CY2023Q3	us-gaap	Inventory Net InventoryNet	17937425
CY2022Q3	us-gaap	Inventory Net InventoryNet	21141501
CY2023	us-gaap	Production Related Impairments Or Charges ProductionRelatedImpairmentsOrCharges	7526727
CY2022	us-gaap	Production Related Impairments Or Charges ProductionRelatedImpairmentsOrCharges	9192865
CY2023Q3	zkin	Property Plant And Equipment Gross Before Construction In Progress PropertyPlantAndEquipmentGrossBeforeConstructionInProgress	13392346
CY2022Q3	zkin	Property Plant And Equipment Gross Before Construction In Progress PropertyPlantAndEquipmentGrossBeforeConstructionInProgress	13174469
CY2023Q3	zkin	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Before Construction In Progress AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentBeforeConstructionInProgress	6456179
CY2022Q3	zkin	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Before Construction In Progress AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentBeforeConstructionInProgress	6061550
CY2023Q3	zkin	Property Plant And Equipment Before Construction In Progress PropertyPlantAndEquipmentBeforeConstructionInProgress	6936167
CY2022Q3	zkin	Property Plant And Equipment Before Construction In Progress PropertyPlantAndEquipmentBeforeConstructionInProgress	7112919
CY2023Q3	zkin	Construction In Progress Net ConstructionInProgressNet	899850
CY2022Q3	zkin	Construction In Progress Net ConstructionInProgressNet	11668
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7836017
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7124587
CY2023	us-gaap	Depreciation Depreciation	677275
CY2023Q3	zkin	Finite Lived Intangible Assets Accumulated Impairment FiniteLivedIntangibleAssetsAccumulatedImpairment	13117788
CY2022Q3	zkin	Finite Lived Intangible Assets Accumulated Impairment FiniteLivedIntangibleAssetsAccumulatedImpairment	2771019
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1766651
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1483125
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1437384
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	11415451
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	10346769
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	298431
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	830481
CY2022Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	74317541
CY2022Q3	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	10447395
CY2022Q3	zkin	Acquired Patent Appraised Value AcquiredPatentAppraisedValue	4990000
CY2023Q3	zkin	Long Term Deposit Written Off LongTermDepositWrittenOff	9830000
CY2023	zkin	Number Of Customers Whose Accounts Receivable Are Sold NumberOfCustomersWhoseAccountsReceivableAreSold	144
CY2023	us-gaap	Accounts Receivable Sale AccountsReceivableSale	65776506
CY2023Q3	zkin	Amount Payable By Buyer Of Accounts Receivable AmountPayableByBuyerOfAccountsReceivable	62487681
CY2023	zkin	Percentage Of Transferred Accounts Receivable Value Payable By Buyer PercentageOfTransferredAccountsReceivableValuePayableByBuyer	0.95
CY2022Q3	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	7522188
CY2022	zkin	Gain Loss On Sale Of Long Term Accounts Receivable GainLossOnSaleOfLongTermAccountsReceivable	1602500
CY2022	us-gaap	Interest And Fee Income Loans Trade Financing InterestAndFeeIncomeLoansTradeFinancing	1151453
CY2023	zkin	Gain Loss On Sale Of Long Term Accounts Receivable GainLossOnSaleOfLongTermAccountsReceivable	1630442
CY2023	us-gaap	Interest And Fee Income Loans Trade Financing InterestAndFeeIncomeLoansTradeFinancing	359051
CY2023Q3	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	3165668
CY2022Q3	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	4054300
CY2023Q3	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	40654
CY2022Q3	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	93282
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1758571
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2802190
CY2023Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	4964893
CY2022Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	6949772
CY2023Q3	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	68500000
CY2023Q3	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	9388706
CY2023Q3	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	62218000
CY2023Q3	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	8527686
CY2022Q3	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	115650000
CY2022Q3	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	16257820
CY2023Q3	us-gaap	Debt Instrument Collateral Amount DebtInstrumentCollateralAmount	2885340
CY2022Q3	us-gaap	Debt Instrument Collateral Amount DebtInstrumentCollateralAmount	2416923
CY2023Q3	us-gaap	Loss Contingency Pending Claims Number LossContingencyPendingClaimsNumber	1
CY2023	zkin	Statute Of Limitations Period To Collect Unpaid Taxes StatuteOfLimitationsPeriodToCollectUnpaidTaxes	P3Y
CY2022	zkin	Provision For Doubtful Accounts On General And Administrative ProvisionForDoubtfulAccountsOnGeneralAndAdministrative	-1876529
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3390733
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	4024284
CY2023	us-gaap	Professional Fees ProfessionalFees	684691
CY2022	us-gaap	Professional Fees ProfessionalFees	1612980
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	298431
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	830481
CY2023	zkin	Depreciation Expenses On General And Administrative DepreciationExpensesOnGeneralAndAdministrative	229018
CY2022	zkin	Depreciation Expenses On General And Administrative DepreciationExpensesOnGeneralAndAdministrative	149156
CY2023	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	173096
CY2022	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	98454
CY2023	us-gaap	Excise And Sales Taxes ExciseAndSalesTaxes	168962
CY2022	us-gaap	Excise And Sales Taxes ExciseAndSalesTaxes	54789
CY2023	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	199409
CY2022	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	527960
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5144340
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5421575
CY2022	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	1394253
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	3947080
CY2023Q3	us-gaap	Debt Instrument Convertible Carrying Amount Of The Equity Component DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent	678782
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	3947080
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	594769
CY2023Q3	zkin	Convertible Debentures ConvertibleDebentures	3352311
CY2023	us-gaap	Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity	678782
CY2023Q3	us-gaap	Debt Instrument Convertible Carrying Amount Of The Equity Component DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent	678782
CY2021	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	550000
CY2021	zkin	Stock Issued During Period Value Share Based Compensations StockIssuedDuringPeriodValueShareBasedCompensations	3149000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1257989
CY2021	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	787880
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	791754
CY2022	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	510120
CY2023	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	250000
CY2021Q2	zkin	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Upon Execution Of Consulting Agreement ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberUponExecutionOfConsultingAgreement	50000
CY2021Q2	zkin	Number Of Stock Options That Vest In Four Equal Installments NumberOfStockOptionsThatVestInFourEqualInstallments	200000
CY2021Q2	zkin	Number Of Equal Installments NumberOfEqualInstallments	4
CY2021Q2	zkin	Number Of Stock Options That Vest Every Three Months NumberOfStockOptionsThatVestEveryThreeMonths	50000
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	250000
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1085386
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	250000
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1085386
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	250000
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P0Y
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0
CY2021Q1	zkin	Number Of Ordinary Shares Issued Upon Execution Of Agreement NumberOfOrdinarySharesIssuedUponExecutionOfAgreement	250000
CY2021Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2500000
CY2021Q1	zkin	Warrants Expiration Term WarrantsExpirationTerm	P9M
CY2021Q1	zkin	Performance Earn Out Shares PerformanceEarnOutShares	1000000
CY2021Q1	zkin	Threshold Operating Net Income For Performance Earn Out Of Ordinary Shares ThresholdOperatingNetIncomeForPerformanceEarnOutOfOrdinaryShares	2500000
CY2022Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	9021000
CY2022	zkin	Warrant Exercise WarrantExercise	0
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4774642
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4774642
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.87
CY2022Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P4Y8M12D
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4774642
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.87
CY2023Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P3Y8M12D
CY2023Q3	zkin	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	4774642
CY2023	zkin	Class Of Warrant Or Right Exercisable Exercise Price Of Warrants ClassOfWarrantOrRightExercisableExercisePriceOfWarrants	2.87
CY2023	zkin	Warrants And Rights Exercisable Term WarrantsAndRightsExercisableTerm	P3Y8M12D
CY2023Q3	us-gaap	Statutory Accounting Practices Statutory Capital And Surplus Required StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired	3176556
CY2022Q3	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	7470323
CY2023Q3	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	7470323
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	2643662
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	301885
CY2021Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	333280
CY2023Q3	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	14972
CY2022Q3	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	15355
CY2021Q3	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	16952
CY2023Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	2850
CY2022Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	2924
CY2021Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	690882
CY2023Q3	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	2661484
CY2021Q3	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	687654
CY2022Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	320164
CY2021Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	353460
CY2022Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	320164
CY2021Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	353460
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-782752
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-1340844
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-958210
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	322897
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	406064
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-459855
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1340844
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-552146
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.15
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.15
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.15
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	1
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.75
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-322897
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-406064
CY2023	zkin	Effective Income Tax Rate Reconciliation Change In Unrecognized Tax Benefits Amount EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTaxBenefitsAmount	-782752
CY2022	zkin	Effective Income Tax Rate Reconciliation Change In Unrecognized Tax Benefits Amount EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTaxBenefitsAmount	-1340844
CY2021	zkin	Effective Income Tax Rate Reconciliation Change In Unrecognized Tax Benefits Amount EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTaxBenefitsAmount	-958210
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-459855
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1340844
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-552146
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.15
CY2023	zkin	Statute Of Limitations Period To Collect Unpaid Taxes StatuteOfLimitationsPeriodToCollectUnpaidTaxes	P3Y
CY2022Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	817059
CY2021Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2354832
CY2020Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3188615
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	38695
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	37407
CY2023	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	785337
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1315945
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	967698
CY2023	zkin	Unrecognized Tax Benefits Increase Decrease Resulting From Foreign Currency Translation UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromForeignCurrencyTranslation	6973
CY2022	zkin	Unrecognized Tax Benefits Increase Decrease Resulting From Foreign Currency Translation UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromForeignCurrencyTranslation	-221828
CY2021	zkin	Unrecognized Tax Benefits Increase Decrease Resulting From Foreign Currency Translation UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromForeignCurrencyTranslation	171322
CY2022Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	817059

Files In Submission

Name	View Source	Status
0001410578-24-001331-index-headers.html	Edgar Link	pending
0001410578-24-001331-index.html	Edgar Link	pending
0001410578-24-001331.txt	Edgar Link	pending
0001410578-24-001331-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
zkin-20230930.xsd	Edgar Link	pending
zkin-20230930x20f.htm	Edgar Link	pending
zkin-20230930x20f001.jpg	Edgar Link	pending
zkin-20230930x20f002.jpg	Edgar Link	pending
zkin-20230930x20f003.jpg	Edgar Link	pending
zkin-20230930x20f004.jpg	Edgar Link	pending
zkin-20230930x20f005.jpg	Edgar Link	pending
zkin-20230930x20f006.jpg	Edgar Link	pending
zkin-20230930x20f007.jpg	Edgar Link	pending
zkin-20230930x20f008.jpg	Edgar Link	pending
zkin-20230930x20f009.jpg	Edgar Link	pending
zkin-20230930x20f010.jpg	Edgar Link	pending
zkin-20230930x20f011.jpg	Edgar Link	pending
zkin-20230930x20f012.jpg	Edgar Link	pending
zkin-20230930x20f013.jpg	Edgar Link	pending
zkin-20230930x20f014.jpg	Edgar Link	pending
zkin-20230930x20f015.jpg	Edgar Link	pending
zkin-20230930x20f017.jpg	Edgar Link	pending
zkin-20230930x20f022.jpg	Edgar Link	pending
zkin-20230930x20f023.jpg	Edgar Link	pending
zkin-20230930x20f024.jpg	Edgar Link	pending
zkin-20230930x20f025.jpg	Edgar Link	pending
zkin-20230930x20f030.jpg	Edgar Link	pending
zkin-20230930x20f033.jpg	Edgar Link	pending
zkin-20230930x20f034.jpg	Edgar Link	pending
zkin-20230930x20f036.jpg	Edgar Link	pending
zkin-20230930x20f037.jpg	Edgar Link	pending
zkin-20230930x20f038.jpg	Edgar Link	pending
zkin-20230930x20f040.jpg	Edgar Link	pending
zkin-20230930x20f042.jpg	Edgar Link	pending
zkin-20230930x20f043.jpg	Edgar Link	pending
zkin-20230930x20f046.jpg	Edgar Link	pending
zkin-20230930x20f047.jpg	Edgar Link	pending
zkin-20230930x20f048.jpg	Edgar Link	pending
zkin-20230930x20f049.jpg	Edgar Link	pending
zkin-20230930x20f055.jpg	Edgar Link	pending
zkin-20230930xex11d2.htm	Edgar Link	pending
zkin-20230930xex12d1.htm	Edgar Link	pending
zkin-20230930xex12d2.htm	Edgar Link	pending
zkin-20230930xex13d1.htm	Edgar Link	pending
zkin-20230930x20f_htm.xml	Edgar Link	completed
zkin-20230930xex13d2.htm	Edgar Link	pending
zkin-20230930xex2d6.htm	Edgar Link	pending
zkin-20230930xex97d1.htm	Edgar Link	pending
zkin-20230930_cal.xml	Edgar Link	unprocessable
zkin-20230930_def.xml	Edgar Link	unprocessable
zkin-20230930_lab.xml	Edgar Link	unprocessable
zkin-20230930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ZKIN
ZK International Group Co., Ltd. Stock $zkin

2023 Q3 Form 20-F Financial Statement

#000141057824001331 Filed on August 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZKIN ZK International Group Co., Ltd. Stock $zkin

2023 Q3 Form 20-F Financial Statement

#000141057824001331 Filed on August 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZKIN
ZK International Group Co., Ltd. Stock $zkin